López-Mínguez JR, Martín de Francisco AL, Soler MJ, Hernández F, Moreno R, Pinar E, Sampedro A, Mareque M, Oyagüez I
Cost-effectiveness analysis of Dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain
Catheter Cardiovasc Interv. 2023;102(2):233-240
Castro Urda JL, Álvarez M, Domínguez-Hernández R, Vázquez M, Castro J, Salinas-Ortega L, Casado MA
Sistema basado en Inteligencia Artificial como ayuda a la decisión clínica y su aplicación al cribado de infección oculta por VHC en el Hospital Universitario Severo Ochoa: Intelligen-C
48º Congreso de la Asociación Española para el estudio del hígado (AEEH). Madrid. 15-17 may 2023
Vargas-Accarino E, Martínez-Campreciós J, Domínguez-Hernández R, Rando-Segura A, Riveiro-Barciela M, Rodríguez-Frías F, Barreira A, Palom A, Casado MA, Esteban R, Buti M
Cost-effectiveness análisis of an active search to retrieve lost-to follow-up HCV patients (RELINK-C strategy): health, economic value and COVID-19 impact
J Viral Hepat. DOI: 10.1111/jvh.13686
Coll P, Jarrín I, Martínez E, Martínez-Sesmero JM, Domínguez-Hernández R, Castro-Gómez A, Casado MA
Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions
Enfermedades Infecciosas y Microbiología Clínica. Doi.org/10.1016/j.eimc.2022.07.012
Esteban R, Domínguez-Hernández R, Martín-Escudero V, Casado MA
Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
Plos One. Doi.org/10.1371/journal.pone.0278544
Mareque M, Climente M, Martinez-Moragon E, Padilla A, Oyagüez I, Touron C, Torres C, Martinez A
Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain
J Asthma. 2023;60(6):1210-1220
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C
Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022
Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J
Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022
Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C